Dushay is an assistant professor of medicine at Harvard Medical School and an attending endocrinologist at Beth Israel Deaconess Medical Center. It makes my head spin to think about how much GLP-1s ...

BEIJING, Feb 14 (Reuters) - China will implement zero‑tariff treatment for imports from the 53 African countries with which it has diplomatic relations, starting May 1, 2026, state media reported on ...

The World Anti-Doping Agency (WADA) said it is now monitoring GLP-1 use among elite athletes, including at the Winter Olympics in Italy. Being ‘monitored’ does not mean a substance is prohibited; ...

Elon Musk's rocket maker SpaceX has acquired artificial intelligence startup xAI in a deal that will value the company at $1.25 trillion, CNBC has confirmed. The transaction comes ahead of a potential ...

Research shows that practicing these two key sleep hygiene roles every night can help you live longer When you purchase through links on our site, we may earn an affiliate commission. Here’s how it ...

Participating Medicare Part D plans can officially begin covering weight-loss treatment in 2027. The initiative falls under CMS’ voluntary “Better Approaches to Lifestyle and Nutrition for ...

On the Wednesday, January 28, 2026, episode of The Excerpt podcast: As GLP-1 use surges, lawsuits allege blindness, stomach paralysis and more. USA TODAY Investigative Reporter Austin Fast breaks down ...

X is putting its money where its mouth is. The Elon Musk-owned social media platform just pledged it will give $1 million to the user who creates the most popular long-form post using its newly ...

Just when you thought the circular deals couldn’t get any more circular, OpenAI has invested in CEO Sam Altman’s brain computer interface (BCI) startup Merge Labs. Merge Labs, which defines itself as ...

On Thursday, OpenAI announced its investment in neurotech startup Merge Labs, cofounded by its CEO, billionaire Sam Altman. OpenAI will collaborate with the new venture to develop technology to link ...

The sustainability of weight-loss drugs is under scrutiny as new research shows that people who stop taking glucagon-like peptide-1 (GLP-1) agonists regain the pounds at a steady rate, returning to ...

GLP-1 weight-loss drugs are more popular than ever. With their ability to increase feelings of fullness and make people eat less, they could not only reshape global food markets but the way people eat ...